Perhaps even more disconcerting is that our analysis of public statements indicates nearly all the top biopharma and medtech firms have experienced significant impacts from disruptions over the past five years.Ĭlearly, most health care companies lack operational resilience, the ability to quickly identify and assess the risk of potential disruptions, react faster when they do occur, and recover from the impacts of these disruptions across the end-to-end (E2E) supply chain. According to a 2022 BCG survey on operational resilience, only 6% of biopharmaceutical and medtech companies are able to anticipate and mitigate the impact of such disruptions. Health care companies are not prepared for the disruptions that have become a recurring theme of today’s business environment. Companies embarking on the journey need to assess their current resilience, build a cohesive resilience strategy, and engage the whole enterprise in the undertaking.īy building robust resilience capabilities, health care companies will put themselves in a better position to thrive and, even more important, to realize their commitment to patients.īy Andres Garro, Jorge Vazquez Anderson, Kevin Reilly, Ben Aylor, and Megan DeFauw.To develop advanced operational resilience, companies typically first learn how to predict and manage risk in the short term and then build the capabilities needed to recover from disruptions faster and be more resilient over the long term.The most resilient health care companies have comprehensive risk identification and mitigation capabilities supported by advanced analytics and owned by the business units.The risks are especially challenging because of the patient-centric and highly regulated nature of the industry. Indeed, nearly all the top biopharma and medtech companies have experienced significant impacts from disruptions over the past five years. In today’s uncertain business environment, only 6% of health care companies have the operational capabilities needed to mitigate disruptions. Technology, Media, and Telecommunications.
0 kommentar(er)
